{"filing":{"accession_number":"0001193125-26-238237","cik":"0001107421","ticker":"TCRT","company_name":"Alaunos Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"tcrt-20260526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312526238237/tcrt-20260526.htm"},"events":[{"id":9016,"run_id":7914,"accession_number":"0001193125-26-238237","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Alaunos announced an integrated preclinical readout for ALN1003, its investigational obesity candidate, disclosing results from non-GLP mouse studies. While this is a material development for a clinical-stage biotech company (affecting investor assessment of pipeline progress), it does not fit neatly into the standard taxonomy—it is neither an earnings release (financial results), nor a clinical trial result (no dedicated 8-K Item), nor a material impairment or litigation event. The disclosure is material because preclinical efficacy data for a lead candidate directly informs investor valuation and risk assessment, warranting classification as other_material.","company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1494,"accession_number":"0001193125-26-238237","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Alaunos announced an integrated preclinical readout for ALN1003, its investigational obesity candidate, disclosing results from non-GLP mouse studies. While this is a material development for a clinical-stage biotech company (affecting investor assessment of pipeline progress), it does not fit neatly into the standard taxonomy—it is neither an earnings release (financial results), nor a clinical trial result (no dedicated 8-K Item), nor a material impairment or litigation event. The disclosure is material because preclinical efficacy data for a lead candidate directly informs investor valuation and risk assessment, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:11:01.426403+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1494,"accession_number":"0001193125-26-238237","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Alaunos announced an integrated preclinical readout for ALN1003, its investigational obesity candidate, disclosing results from non-GLP mouse studies. While this is a material development for a clinical-stage biotech company (affecting investor assessment of pipeline progress), it does not fit neatly into the standard taxonomy—it is neither an earnings release (financial results), nor a clinical trial result (no dedicated 8-K Item), nor a material impairment or litigation event. The disclosure is material because preclinical efficacy data for a lead candidate directly informs investor valuation and risk assessment, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:11:01.426403+00:00","company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","filing_date":"2026-05-26"}]}